Cargando…
Ending TB in South-East Asia: flagship priority and response transformation
Over the decades, the global tuberculosis (TB) response has evolved from sanatoria-based treatment to DOTS (Directly Observed Therapy Shortcourse) strategy and the more recent End TB Strategy. The WHO South-East Asia Region, which accounted for 45% of new TB patients and 50% of deaths globally in 20...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667305/ https://www.ncbi.nlm.nih.gov/pubmed/38028166 http://dx.doi.org/10.1016/j.lansea.2023.100301 |
_version_ | 1785139218161336320 |
---|---|
author | Bhatia, Vineet Rijal, Suman Sharma, Mukta Islam, Akramul Vassall, Anna Bhargava, Anurag Thida, Aye Basri, Carmelia Onozaki, Ikushi Pai, Madhukar Rezwan, Md Kamar Arinaminpathy, Nim Chandrashekhar, Padmapriyadarsini Sarin, Rohit Mandal, Sandip Raviglione, Mario |
author_facet | Bhatia, Vineet Rijal, Suman Sharma, Mukta Islam, Akramul Vassall, Anna Bhargava, Anurag Thida, Aye Basri, Carmelia Onozaki, Ikushi Pai, Madhukar Rezwan, Md Kamar Arinaminpathy, Nim Chandrashekhar, Padmapriyadarsini Sarin, Rohit Mandal, Sandip Raviglione, Mario |
author_sort | Bhatia, Vineet |
collection | PubMed |
description | Over the decades, the global tuberculosis (TB) response has evolved from sanatoria-based treatment to DOTS (Directly Observed Therapy Shortcourse) strategy and the more recent End TB Strategy. The WHO South-East Asia Region, which accounted for 45% of new TB patients and 50% of deaths globally in 2021, is pivotal to the global fight against TB. “Accelerate Efforts to End TB” by 2030 was adopted as a South-East Asia Regional Flagship Priority (RFP) in 2017. This article illustrates intensified and transformed approaches to address the disease burden following the adoption of RFP and new challenges that emerged during the COVID-19 pandemic. TB case notifications improved by 25% and treatment success rates improved by 6% between 2016 and 2019 due to interventions ranging from galvanising political commitments to empowering and engaging communities. Cumulative TB programme budget allocations in 2022 reached US$ 1.4 billion, about two and a half times the budget in 2016. An ambitious Regional Strategic Plan towards ending TB, 2021–2025, identifies priority interventions that will need investments of up to US$ 3 billion a year to fully implement them. Moving forward, countries in the Region need to leverage RFP and take up intensified, people-centred, holistic interventions for prevention, diagnosis, treatment and care of TB with commensurate investments and cross-ministerial and multi-sectoral coordination. |
format | Online Article Text |
id | pubmed-10667305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106673052023-10-29 Ending TB in South-East Asia: flagship priority and response transformation Bhatia, Vineet Rijal, Suman Sharma, Mukta Islam, Akramul Vassall, Anna Bhargava, Anurag Thida, Aye Basri, Carmelia Onozaki, Ikushi Pai, Madhukar Rezwan, Md Kamar Arinaminpathy, Nim Chandrashekhar, Padmapriyadarsini Sarin, Rohit Mandal, Sandip Raviglione, Mario Lancet Reg Health Southeast Asia Health Policy Over the decades, the global tuberculosis (TB) response has evolved from sanatoria-based treatment to DOTS (Directly Observed Therapy Shortcourse) strategy and the more recent End TB Strategy. The WHO South-East Asia Region, which accounted for 45% of new TB patients and 50% of deaths globally in 2021, is pivotal to the global fight against TB. “Accelerate Efforts to End TB” by 2030 was adopted as a South-East Asia Regional Flagship Priority (RFP) in 2017. This article illustrates intensified and transformed approaches to address the disease burden following the adoption of RFP and new challenges that emerged during the COVID-19 pandemic. TB case notifications improved by 25% and treatment success rates improved by 6% between 2016 and 2019 due to interventions ranging from galvanising political commitments to empowering and engaging communities. Cumulative TB programme budget allocations in 2022 reached US$ 1.4 billion, about two and a half times the budget in 2016. An ambitious Regional Strategic Plan towards ending TB, 2021–2025, identifies priority interventions that will need investments of up to US$ 3 billion a year to fully implement them. Moving forward, countries in the Region need to leverage RFP and take up intensified, people-centred, holistic interventions for prevention, diagnosis, treatment and care of TB with commensurate investments and cross-ministerial and multi-sectoral coordination. Elsevier 2023-10-29 /pmc/articles/PMC10667305/ /pubmed/38028166 http://dx.doi.org/10.1016/j.lansea.2023.100301 Text en © 2023 Published by Elsevier Ltd. https://creativecommons.org/licenses/by/3.0/igo/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/igo/). |
spellingShingle | Health Policy Bhatia, Vineet Rijal, Suman Sharma, Mukta Islam, Akramul Vassall, Anna Bhargava, Anurag Thida, Aye Basri, Carmelia Onozaki, Ikushi Pai, Madhukar Rezwan, Md Kamar Arinaminpathy, Nim Chandrashekhar, Padmapriyadarsini Sarin, Rohit Mandal, Sandip Raviglione, Mario Ending TB in South-East Asia: flagship priority and response transformation |
title | Ending TB in South-East Asia: flagship priority and response transformation |
title_full | Ending TB in South-East Asia: flagship priority and response transformation |
title_fullStr | Ending TB in South-East Asia: flagship priority and response transformation |
title_full_unstemmed | Ending TB in South-East Asia: flagship priority and response transformation |
title_short | Ending TB in South-East Asia: flagship priority and response transformation |
title_sort | ending tb in south-east asia: flagship priority and response transformation |
topic | Health Policy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667305/ https://www.ncbi.nlm.nih.gov/pubmed/38028166 http://dx.doi.org/10.1016/j.lansea.2023.100301 |
work_keys_str_mv | AT bhatiavineet endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT rijalsuman endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT sharmamukta endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT islamakramul endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT vassallanna endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT bhargavaanurag endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT thidaaye endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT basricarmelia endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT onozakiikushi endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT paimadhukar endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT rezwanmdkamar endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT arinaminpathynim endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT chandrashekharpadmapriyadarsini endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT sarinrohit endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT mandalsandip endingtbinsoutheastasiaflagshippriorityandresponsetransformation AT raviglionemario endingtbinsoutheastasiaflagshippriorityandresponsetransformation |